Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DC5NS1
|
|||
| Drug Name |
PT320
|
|||
| Drug Type |
Peptide
|
|||
| Indication | Parkinson disease [ICD-11: 8A00.0; ICD-10: F02.3, G20; ICD-9: 332] | Phase 2 | [1] | |
| Company |
Peptron, Inc.
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glucagon (GCG) | Target Info | Agonist | [2] |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Thermogenesis | ||||
| Insulin secretion | ||||
| Glucagon signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04269642) Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Sustained Release GLP-1 Agonist PT320 Delays Disease Progression in a Mouse Model of Parkinson's Disease. ACS Pharmacol Transl Sci. 2021 Mar 16;4(2):858-869. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.